Informations générales (source: ClinicalTrials.gov)
Anti-tumor Specific Immune Response in Head and Neck Cancers (CORISAT)
Observational
Central Hospital, Nancy, France (Voir sur ClinicalTrials)
mars 2017
mars 2021
29 juin 2024
The purpose is the description of anti-tumor immune responses in general and according to
clinical stage and disease free survival (DFS: survival without recurrence (local or
distant)) in patients with Head & Neck Squamous Cell Carcinoma
Secondary purposes are:
- Study of relationship between anti-tumor immune response and qualitative (yes/no)
and quantitative (number) presence of circulating tumor cells (CTCs);
- Study of relationship between qualitative (yes/no) and quantitative (number)
presence of CTCs and clinical stage as well as DFS
- Study of relationship between anti-tumor immune response and clinical stage as well
as DFS.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Institut de Cancérologie Alexis Vautrin - Vandoeuvre les Nancy - France | Gilles DOLIVET | Contact (sur clinicalTrials) | |||
| Service d'ORL - CHRU DIJON - Dijon - France | Contact (sur clinicalTrials) | ||||
| Service d'ORL - CHRU REIMS - Reims - France | Contact (sur clinicalTrials) | ||||
| Service ORL - Institut Louis Mathieu - CHRU NANCY - Vandoeuvre les Nancy - France | Patrice GALLET | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Service d'ORL - CHRU BESANCON - Besancon - France | Olivier MAUVAIS | Contact (sur clinicalTrials) | |||
| Service d'ORL - CHRU STRASBOURG - Strasbourg - France | Philippe SCHULTZ | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Patient with Head & Neck Squamous Cell Carcinoma after extension assessment,
regardless of clinical stage (TNM UICC stage I-IV), before any medical or surgical
treatment specifically directed against cancer (radiotherapy, surgery, chemotherapy
or targeted therapy)
- Consent to participate to the study, non-opposition
- Affiliation to social security
- Patient with Head & Neck Squamous Cell Carcinoma after extension assessment,
regardless of clinical stage (TNM UICC stage I-IV), before any medical or surgical
treatment specifically directed against cancer (radiotherapy, surgery, chemotherapy
or targeted therapy)
- Consent to participate to the study, non-opposition
- Affiliation to social security
- History of neoplasia, synchronous cancer, auto-immune disease, organ
transplantation, chemotherapy
- HIV infection
- Corticotherapy during 15 days before blood sampling